RareCyte® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate both ARv7 and SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer. The ARv7/Synaptophysin Panel Kit was validated based on rigorous requirements set to clinical standards…
Read More
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), achieved the on-schedule completion of a drug substance Process Performance Qualification (PPQ) campaign, focused on teplizumab  (PRV-031) for partner Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases. The PPQ campaign consisted of three commercial scale runs required for the validation of Provention Bio’s drug…
Read More
UW Medicine is one of a network of U.S. sites testing a new treatment for COVID-19 that involves monoclonal antibodies, which are intended to provide immediate antiviral activity that lasts several weeks. The drug is part of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, sponsored by the National Institute of Allergy and Infectious Diseases. The trial is also receiving…
Read More

Silverback Therapeutics Initiates Phase I Clinical Study of SBT6050

Silverback Therapeutics (“Silverback”), a biopharmaceutical company advancing a pipeline of therapies that are systemically delivered but locally active, today announced initiation of a Phase 1 clinical study of SBT6050, a novel therapeutic comprising a specific small molecule toll-like receptor 8 (TLR8) agonist conjugated to a HER2-directed monoclonal antibody. “SBT6050 is designed for systemic administration and tumor-localized activation of myeloid cells, in…
Read More
A Phase 1 patient trial of the novel, oral therapy candidate, alpha-TEA, for advanced HER2 positive breast cancer is now underway.  Veana Therpeutics, Inc., and UW Medicine will collaborate on the clinical testing of Veana’s lead agent – an alpha TEA lysine salt, in combination with the monoclonal antibody, trastuzumab, brand name Herceptin. In HER2 positive breast cancer, the tumor cells produce a higher-than-usual level of the…
Read More
Scientists have demonstrated a new way to precisely target cells by distinguishing them from neighboring cells that look quite similar. Even cells that become cancerous may differ from their healthy neighbors in only a few subtle ways. A central challenge in the treatment of cancer and many other diseases is being able to spot the right cells while sparing all…
Read More
Last week the National Cancer Institute released some good news for patients with lung cancer: improved treatments are driving down the death rate. But there’s a snag — the findings only apply to the most common lung cancer type, non-small cell lung cancer. People with small cell lung cancer, a less common but more aggressive type, have yet to see treatment…
Read More
Humans do not develop disease overnight. Rather, diseases develop gradually over years — sometimes decades — before symptoms appear, and are due to malfunctioning physiological processes brought about by our genes and environment. In research just published in the journal Proceedings of the National Academy of Sciences (PNAS), scientists from Institute for Systems Biology (ISB) and partner institutions have shown how an…
Read More

A New Map Catalogs the Effects of Coronavirus Mutations

HHMI scientists are joining many of their colleagues worldwide in working to combat the new coronavirus. They’re developing diagnostic testing, understanding the virus’s basic biology, modeling the epidemiology, and developing potential therapies or vaccines. Over the next several weeks, we will be sharing stories of some of this work. SARS-CoV-2 infects human cells by binding to a protein called ACE2 (grey).…
Read More
Chinook Therapeutics, a biotech company creating targeted therapies for kidney diseases, raised an additional $106 million just before its planned merger with Aduro Biotech. Chinook said it will have at least $275 million in operating capital following the investment and merger. New investors include EcoR1 Capital, OrbiMed, funds managed by Rock Springs Capital, Avidity Partners, Surveyor Capital (a Citadel company),…
Read More